

Formulary Update

November 2021

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since September 2021. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Evra®	Combined hormonal contraceptive patch for women who have demonstrated-, or are deemed to be at-, substantial risk of poor compliance with combined oral contraceptives.	7.3.1.6 Total Formulary	Formulary appeal
Ezetimibe	Monotherapy for secondary prevention of cardiovascular events when statins are not tolerated.	2.11 Total Formulary	Formulary appeal
Thealoz Duo® eye drops	For severe dry eyes when Blink Intensive Tears and Evolve HA are not appropriate and the addition of trehalose is desirable (corneal damage).	11.2.8 Total Formulary	Formulary appeal
Changes in preferred brand	New preferred brand	Adult Medicines Formulary entry	
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Inhaler devices	Inhaler device guides updated regarding preferred medicines and products, access guides via Prescribing Resources	3.1, 3.2	MCN formulary section review
dapagliflozin	Removal of indication for type 1 diabetes mellitus	6.1	UK licence withdrawn for this specific indication

Contact us [here](#)